Botanix Pharmaceuticals Ltd Cash Flow Conversion Efficiency
Botanix Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has a cash flow conversion efficiency ratio of -0.591x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-48.02 Million ≈ $-33.98 Million USD) by net assets (AU$81.30 Million ≈ $57.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Botanix Pharmaceuticals Ltd (1991–2025)
Cash flow conversion efficiency of Botanix Pharmaceuticals Ltd from 1991 to 2025. This chart illustrates how Botanix Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Botanix Pharmaceuticals Ltd (BOT) share price today for real-time trading data and today's change.
Botanix Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained
Botanix Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Botanix Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see BOT company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Relpol SA
WAR:RLP
|
-0.019x |
|
Andira Agro Tbk PT
JK:ANDI
|
-0.114x |
|
Enry S Island Spa Sb
VI:EIOS
|
N/A |
|
DATRIX S.P.A.
F:BW6
|
N/A |
|
Pardus Girisim Sermayesi Yatirim Ortakligi A.S.
IS:PRDGS
|
0.024x |
|
Sphere 3D Corp
NASDAQ:ANY
|
-0.373x |
|
Domo Activos Socimi SA
MC:DOMO
|
-0.014x |
|
Polwax SA
WAR:PWX
|
-0.416x |
Annual Cash Flow Conversion Efficiency for Botanix Pharmaceuticals Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Botanix Pharmaceuticals Ltd from 1991 to 2025. Review Botanix Pharmaceuticals Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$81.30 Million ≈ $57.52 Million |
AU$-78.58 Million ≈ $-55.60 Million |
-0.967x | -1193.21% |
| 2024-06-30 | AU$108.73 Million ≈ $76.94 Million |
AU$-8.13 Million ≈ $-5.75 Million |
-0.075x | +85.79% |
| 2023-06-30 | AU$22.95 Million ≈ $16.24 Million |
AU$-12.07 Million ≈ $-8.54 Million |
-0.526x | +61.66% |
| 2022-06-30 | AU$8.15 Million ≈ $5.77 Million |
AU$-11.18 Million ≈ $-7.91 Million |
-1.372x | -861.49% |
| 2021-06-30 | AU$20.80 Million ≈ $14.72 Million |
AU$-2.97 Million ≈ $-2.10 Million |
-0.143x | +80.57% |
| 2020-06-30 | AU$23.64 Million ≈ $16.72 Million |
AU$-17.36 Million ≈ $-12.28 Million |
-0.734x | +96.56% |
| 2019-06-30 | AU$615.22K ≈ $435.30K |
AU$-13.14 Million ≈ $-9.30 Million |
-21.360x | -3410.32% |
| 2018-06-30 | AU$16.28 Million ≈ $11.52 Million |
AU$-9.91 Million ≈ $-7.01 Million |
-0.608x | +28.70% |
| 2017-06-30 | AU$5.44 Million ≈ $3.85 Million |
AU$-4.64 Million ≈ $-3.28 Million |
-0.853x | -40490.24% |
| 2016-06-30 | AU$3.18 Million ≈ $2.25 Million |
AU$-6.69K ≈ $-4.73K |
-0.002x | +99.79% |
| 2015-06-30 | AU$1.23 Million ≈ $869.58K |
AU$-1.20 Million ≈ $-851.81K |
-0.980x | -70.31% |
| 2014-06-30 | AU$2.24 Million ≈ $1.59 Million |
AU$-1.29 Million ≈ $-913.02K |
-0.575x | -238.34% |
| 2013-06-30 | AU$-2.50 Million ≈ $-1.77 Million |
AU$-1.04 Million ≈ $-735.77K |
0.416x | -13.19% |
| 2012-06-30 | AU$-2.33 Million ≈ $-1.65 Million |
AU$-1.12 Million ≈ $-790.81K |
0.479x | +54.21% |
| 2011-06-30 | AU$-2.23 Million ≈ $-1.58 Million |
AU$-692.97K ≈ $-490.32K |
0.311x | -35.20% |
| 2010-06-30 | AU$-1.80 Million ≈ $-1.27 Million |
AU$-861.12K ≈ $-609.30K |
0.479x | +125.99% |
| 2009-06-30 | AU$877.74K ≈ $621.06K |
AU$-1.62 Million ≈ $-1.15 Million |
-1.844x | +0.15% |
| 2008-06-30 | AU$1.29 Million ≈ $909.99K |
AU$-2.38 Million ≈ $-1.68 Million |
-1.847x | -94.45% |
| 2007-06-30 | AU$2.90 Million ≈ $2.05 Million |
AU$-2.75 Million ≈ $-1.95 Million |
-0.950x | +29.94% |
| 2006-06-30 | AU$2.22 Million ≈ $1.57 Million |
AU$-3.01 Million ≈ $-2.13 Million |
-1.356x | -64.76% |
| 2005-06-30 | AU$3.46 Million ≈ $2.45 Million |
AU$-2.84 Million ≈ $-2.01 Million |
-0.823x | -213.18% |
| 2004-06-30 | AU$2.24 Million ≈ $1.59 Million |
AU$-589.68K ≈ $-417.24K |
-0.263x | +9.32% |
| 2002-06-30 | AU$4.05 Million ≈ $2.86 Million |
AU$-1.17 Million ≈ $-829.68K |
-0.290x | -395.90% |
| 2001-06-30 | AU$5.69 Million ≈ $4.03 Million |
AU$-332.70K ≈ $-235.40K |
-0.058x | +80.44% |
| 2000-06-30 | AU$5.15 Million ≈ $3.64 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.299x | +45.25% |
| 1999-06-30 | AU$8.08 Million ≈ $5.72 Million |
AU$-4.41 Million ≈ $-3.12 Million |
-0.546x | -218.85% |
| 1998-06-30 | AU$15.75 Million ≈ $11.15 Million |
AU$7.23 Million ≈ $5.12 Million |
0.459x | +547.35% |
| 1997-06-30 | AU$32.05 Million ≈ $22.67 Million |
AU$-3.29 Million ≈ $-2.33 Million |
-0.103x | -8556.45% |
| 1996-06-30 | AU$37.91 Million ≈ $26.83 Million |
AU$46.00K ≈ $32.55K |
0.001x | -99.25% |
| 1995-06-30 | AU$38.44 Million ≈ $27.20 Million |
AU$6.24 Million ≈ $4.42 Million |
0.162x | +68.58% |
| 1994-06-30 | AU$26.04 Million ≈ $18.43 Million |
AU$2.51 Million ≈ $1.78 Million |
0.096x | +25.35% |
| 1993-06-30 | AU$18.35 Million ≈ $12.98 Million |
AU$1.41 Million ≈ $997.66K |
0.077x | -39.42% |
| 1992-06-30 | AU$11.41 Million ≈ $8.07 Million |
AU$1.45 Million ≈ $1.02 Million |
0.127x | -15.46% |
| 1991-06-30 | AU$12.88 Million ≈ $9.11 Million |
AU$1.93 Million ≈ $1.37 Million |
0.150x | -- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more